Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.55 |
| ▸ | CNR1 | P21554 | 6/20 | 0.55 |
| ▸ | KIF11 | P52732 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096345 | 0.93 | CNR1 (0.48) | CNR2CNR1KIF11KCNH2RELA | |
| SCHEMBL23026417 | 0.87 | KIF11 (0.43) | CNR2CNR1KIF11KCNH2RELA | |
| SCHEMBL14025162 | 0.86 | CNR2 (0.68) | CNR2CNR1 | |
| SCHEMBL5646550 | 0.85 | CNR2 (0.60) | CNR2CNR1KIF11ACHE | |
| SCHEMBL15995315 | 0.83 | CNR2 (0.49) | CNR2CNR1KIF11MAOBCYP3A4 | |
| SCHEMBL5644608 | 0.81 | CNR1 (0.52) | CNR2CNR1KIF11MAOBACHE | |
| SCHEMBL7166616 | 0.80 | CNR2 (0.53) | CNR2CNR1ALDH1A1 | |
| SCHEMBL18519141 | 0.79 | NFE2L2 (0.46) | CNR2CNR1KIF11KCNH2RELA | |
| SCHEMBL4888686 | 0.78 | CNR2 (0.47) | CNR2CNR1ACHE | |
| SCHEMBL3435840 | 0.78 | KIF11 (0.46) | CNR2CNR1KIF11MAOBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230250117-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | CNR2 1569/4885CNR1 1618/4885KIF11 4039/4885 |
| US-20230250117-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | CNR2 1569/4885CNR1 1618/4885KIF11 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.